In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Soleno Therapeutics, Inc. is one of them. Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for being one of the most oversold stocks. It is a clinical-stage biotech focused on rare diseases and has seen significant stock volatility in 2025 following the commercial launch of its lead product, VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS). The therapy addresses ...

Group 1 - Soleno Therapeutics (NASDAQ: SLNO) recently received approval for its drug Vykat (diazoxide choline) aimed at treating patients over 4 years old with Prader-Willi syndrome [1] - The article promotes a weekly newsletter that provides insights into stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - The investing group Haggerston BioHealth, led by a biotech consultant with over 5 years of experience, offers detailed reports on more than 1,000 companies, including sales forecasts and financial analyses [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product, Vykat XR, which led to a significant drop in the company's stock price [1][2]. Group 1: Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO [1]. - The company's only product, Vykat XR, has been criticized as overpriced and potentially unsafe for children according to a report by Scorpion Capital [2]. Group 2: Stock Performance - Following the publication of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

A downtrend has been apparent in Soleno Therapeutics, Inc. (SLNO) lately with too much selling pressure. The stock has declined 26% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock i ...

OAKLAND, Calif.--(BUSINESS WIRE)---- $SLNO #SLNO--Gibbs Mura is investigating legal claims on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO). ...

LOS ANGELES--(BUSINESS WIRE)---- $SLNO--SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm. ...

Group 1 - Deep-pocketed investors have adopted a bearish approach towards Soleno Therapeutics, indicating that significant market movements may be imminent [1][2] - Among heavyweight investors, 32% are bullish while 51% are bearish, with notable options activity including 8 puts totaling $504,980 and 23 calls amounting to $1,156,660 [2] - The projected price targets for Soleno Therapeutics are between $55.0 and $70.0, based on the analysis of volume and open interest in options contracts [3] Group 2 - The average open interest for Soleno Therapeutics options is 476.88, with total volume reaching 23,916.00, indicating heightened trading activity [4] - Recent options activity includes various trades with significant total trade prices, such as a bullish put trade for $164.4K and a bearish call trade for $136.4K [9] - Soleno Therapeutics is currently trading at $61.83, down by -11.94%, with a trading volume of 5,714,276 [15] Group 3 - Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its product candidate DCCR showing promise in activating KATP channels [11] - Professional analysts have set an average price target of $113.0 for Soleno Therapeutics, with varying ratings from different firms [12][13]

Shares of Soleno Therapeutics (NASDAQ:SLNO) fell on Wednesday after a federal database indicated that a 17-year-old male treated with the company’s recently launched rare disease therapy Vykat XR had died. The report comes months after the Redwood City, California-based biotech launched ...

Soleno Therapeutics said on Wednesday it is aware of the death of a 17 year old male who was on the company's treatment for patients who experience feelings of intense and persistent hunger, sending i... ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Soleno Therapeutics securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Soleno Therapeutics [2]. Group 2: Stock Performance and Concerns - On August 15, 2025, Soleno Therapeutics' stock fell 7.4% following a short report from Scorpion Capital that raised serious concerns about its treatment for Prader-Willi syndrome, VYKAT XR [3]. - The Scorpion Capital report highlighted personal safety issues and suggested that the drug might face withdrawal from the market or a significant decline in new prescriptions [3]. - The stock experienced an additional decline of 4.9% on the next trading day after the initial drop [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].